Table 1 Patient demographics at baseline (week 0, safety analysis set and per protocol analysis set)
Safety set | Per protocol set | |||
|---|---|---|---|---|
Lanthanum carbonate | Placebo | Lanthanum carbonate | Placebo | |
(n = 23) | (n = 12) | (n = 17) | (n = 12) | |
Age, years | ||||
Mean (SD) | 66.0 (13.9) | 69.4 (13.2) | 65.6 (14.7) | 69.4 (13.2) |
Median | 65.0 | 72.5 | 65 | 73 |
Range | 38–84 | 43–87 | 38–84 | 43–87 |
Gender, n (%) | ||||
Male | 13 (56.5) | 5 (41.7) | 10 (58.8) | 5 (41.7) |
Ethnicity, n (%) | ||||
White | 16 (69.6) | 9 (75) | 12 (70.6) | 9 (75.0) |
Black | 6 (26.1) | 2 (16.7) | 5 (29.4) | 2 (16.7) |
Asian | 0 (0.0) | 1 (8.3) | 0 (0.0) | 1 (8.3) |
Body mass index, kg/m2, mean (SD) | 29.9 (5.1) | 30.1 (5.1) | 29.4 (4.9) | 30.1 (5.1) |
iGFR (ml/min/1.73 m2), mean (SD) | 42.5 (10.7) | 48.0 (13.1) | 42.2 (10.1) | 48.0 (13.1) |